InnovHeart is a highly innovative clinical stage Italian start-up founded in 2015 that is developing Saturn, a novel Transcatheter Mitral Valve Replacement (TMVR) technology for the treatment of mitral regurgitation.
The Saturn platform is based on a unique approach of delivering and anchoring the implant with the potential to provide significant advantages over first generation systems and the ability to treat a large and more heterogeneous patients population.
The platform is designed for both Trans-apical and Trans-septal valve delivery and it will help many patients in the world suffering of mitral regurgitation without the need of undergoing an invasive surgery.
The Saturn platform is based on a unique approach of delivering and anchoring the implant with the potential to provide significant advantages over first generation systems and the ability to treat a large and more heterogeneous patients population.
The platform is designed for both Trans-apical and Trans-septal valve delivery and it will help many patients in the world suffering of mitral regurgitation without the need of undergoing an invasive surgery.
Total raised: $78.58M
Investors 3
Funding Rounds 2
| Date | Series | Amount | Investors |
| 27.01.2022 | Series C | $55M | - |
| 07.08.2020 | Series B | $23.58M | - |
Mentions in press and media 6
| Date | Title | Description |
| 27.01.2022 | InnovHeart opens the funding valve with $55M to usher mitral system through clinical trials | InnovHeart may not have grown three sizes in one day, but it’s gotten quite a boost from the recent close of its series C funding round. The Milan-based company makes transcatheter mitral valve replacement (TMVR) systems designed to treat m... |
| 27.01.2022 | InnovHeart opens the funding valve with $55M to usher mitral system through clinical trials | InnovHeart may not have grown three sizes in one day, but it’s gotten quite a boost from the recent close of its series C funding round. The funding was led by China’s Grand Pharmaceutical Group, with additional participation from existing ... |
| 27.01.2022 | InnovHeart raises $55 million in Series C financing to further develop the Trans-septal Saturn Transcatheter Mitral Valve Replacement System | MILAN, Jan. 27, 2022 /PRNewswire/ -- InnovHeart s.r.l., a developer of novel Transcatheter Mitral Valve Replacement (TMVR) systems for the treatment of mitral valve disease, announces the closing of its Series C financing with granting an e... |
| 12.01.2021 | Azin Parhizgar, Ph.D. Joins InnovHeart as Independent Member of the Board of Directors | |
| 07.08.2020 | Transcatheter Mitral Valve Replacement Company InnovHeart Closes Series B Financing of €20 Million | Transcatheter Mitral Valve Replacement Company InnovHeart Closes Series B Financing of €20 Million InnovHeart s.r.l., a developer of novel Transcatheter Mitral Valve Replacement (TMVR) systems for the treatment of mitral valve disease, anno... |
| 07.08.2020 | InnovHeart Closes Series B Financing of €20 Million | NEWTON, Mass.--(BUSINESS WIRE)--InnovHeart s.r.l., a developer of novel Transcatheter Mitral Valve Replacement (TMVR) systems for the treatment of mitral valve disease, announced today the closing of a €20 million round of equity financing.... |